Metastatic type 1 gastric carcinoid: A real threat or just a myth?

Table 1 Clinical and histopathological characteristics of the study patients

Patient No.	No. of lesions	Size, largest lesion (mm)	Ki-67%	CT before Tx	SRS/68Ga before Tx	Distant mets	Gastrin (40-108 mU/L)		Surgery	Residual disease	SSA/monthly dosage (mg)	Outcome	F/U Period (mo)
							at Dx	Last
1	multiple	15	2%	-	Uptake (stomach, LN)	no	1811	125	wedge resection	no	Som A 90	cure	108
2	solitary	35	2%	Liver mets	Uptake (stomach, Liver)	liver	-	-	Billroth 2 + LN	liver	no	SD	84
3	multiple	21	2%	Liver mets	Uptake (stomach, Liver)	liver	2204	325	none	liver	San LAR 30	CR	36
4	multiple	55	20%	Stomach lesion	Uptake (stomach)	diaphragm	1800	-	Billroth 2 + LN	no	San LAR 30	cure	24
5	multiple	25	1%	Stomach lesion	Uptake (stomach, LN)	no	1403	-	Billroth 2 + LN	no	no	cure	18
6	multiple	-	15%	Hepato-gastric ligament LN	no data	no	-	-	ER	no	no	cure	12
7	solitary	17	4%	LN	Uptake (stomach, LN)	no	700	600	wedge resection	no	no	cure	132
8	multiple	15	1%	Liver mets and LN	Uptake (LN, Liver)	liver	407	190	ER, largest	liver	San LAR 30 + INF 50 mcg/wk	PR	36
9	solitary	10	1%	Liver mets and LN	no data	liver	-	-	wedge resection	no	no	cure	360
10	solitary	30	5%	Stomach lesion	no uptake	no	5130	43	Billroth 2 + LN	no	none	cure	120
11	multiple	17	1%	-	no uptake	no	-	-	Billroth 2 + LN	no	none	cure	168
12	multiple	14	5%	-	no uptake	no	-	-	Billroth 2 + LN	no	none	cure	72
13	solitary	47	15%	-	Uptake (stomach, Liver)	liver	5470	45	ER	liver	none	SD	120
14	multiple	30	2%	-	Uptake (LN, Liver)	liver	1336	335	ER, recurrent	liver	none	SD	48
15	multiple	10	2%	No pathology	no uptake	no	3500	-	Billroth 2 + LN	no	none	cure	48
16	multiple	30	2%	Stomach lesion	no data	no	-	-	Billroth 2 + LN	no	none	cure	36
17	solitary	-	1%	Liver mets	Uptake (liver)	liver	1612	10	Billroth 2 + LN	liver	none	SD	36
18	multiple	20	-	Stomach lesion, mesenteric and gastro-hepatic LN	no data	no	506	-	wedge resection	no	none	cure	60
19	multiple	20	-	No pathology	no uptake	no	1600	-	Billroth 2 + LN	no	none	cure	72
20	multiple	15	-	Liver mets	Uptake (stomach, Liver)	liver	458	336	ER	liver	San LAR 30	SD	72

Nr. of lesions, solitary: one lesion seen on endoscopy, multiples ≥ 2 lesions seen on endoscopy; CT: Computerized tomography; SRS: Somatostatin receptor scintigraphy (Octreoscan); (68)Ga: (68)Gallium-DOTA-TATE/-TOC/-NOC PET; Tx: Treatment; SSAs: Somatostatin analogues; LN: Lymphadenopathy; mets: Metastases; SomA: Somatuline Autogel; SanLAR: Sandostatin LAR; INF: Interferon α; Billroth 2 + LN: Gastro-jejunostomy and lymph nodes dissection; wedge resection: wedge resection (triangular resection) of a part of the stomach; ER: Endoscopic resection; SD: Stable disease; PR: Partial response; CR: Complete response.